Dr. Jonathan R. Strosberg, MD

Dr. Strosberg practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Strosberg's NPI, 1013960988, was assigned on May 19, 2006. Dr. Strosberg graduated from Weill Cornell Medicine in 1999. Dr. Strosberg holds Florida license ME87326.

Dr. Strosberg's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Strosberg's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Strosberg practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Strosberg's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Strosberg is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Strosberg's licenses on file in 4 states: Florida, District of Columbia, Montana and Virginia.

Dmand AI lists colorectal cancer and prostate cancer among the conditions Dr. Strosberg treats.

CMS data shows 464 Medicare services from Dr. Strosberg across 6 procedure codes in 2024, for 201 Medicare patients. Medicare paid $31,255 for them.

CMS counts 201 Medicare patients who saw Dr. Strosberg in 2024. The largest group is 65 to 74, with 106 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Strosberg's median patient age at 68, with 53% women.

In 2024, Dr. Strosberg wrote 721 Medicare Part D claims for 135 patients. 81% of them were for generic drugs. CMS names the drug for 542 of them, across 22 drugs with 11 or more claims each, at $249,774 in total drug cost. In 2023, CMS named 476 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Strosberg for performance year 2024, reported as part of a group. Dr. Strosberg accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Strosberg as offering telehealth.

Dmand AI links 219 papers to Dr. Strosberg, published from 2006 to 2025. 2021 was the busiest year, with 18. The most frequent topics are Neuroendocrine Tumors, Pancreatic Neoplasms and Intestinal Neoplasms. Dr. Strosberg has published most often in Pancreas. Dr. Strosberg's most frequent co-authors are Larry Kvols, MD, Domenico Coppola, MD and James C. Yao, MD.

Dmand AI links Dr. Strosberg to 20 clinical trials, 14 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Neuroendocrine Tumors, Carcinoid Tumor and Neoplasm Metastasis. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 10.

CMS Open Payments shows 289 general payments to Dr. Strosberg from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 38% of the total. Ipsen Biopharmaceuticals, Inc paid the most, $83,181. It also lists 1 research payment totaling $7,186 in 2018.

Dr. Strosberg graduated from Weill Cornell Medicine in 1999.

Dr. Strosberg is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.